Aims To investigate the pharmacokinetics and safety profile of JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glycoloylpyrrolidinyl]-2-pyrrolidinecarboxamide, a novel specific orally active prolyl endopeptidase (PEP) inhibitor. Methods JTP-4819 was given orally to 28 healthy male volunteers at single doses of 30 mg (n=6), 60 mg (n=6), 120 mg (n=6) and placebo (n=3) and multiple doses of 60 mg three times daily (n=5) and placebo (n=2) for 7 days to investigate its safety and pharmacokinetics following a preliminary safety evaluation of 3, 10 and 30 mg doses in six healthy volunteers. With the single dose of 60 mg, a cross-over study was conducted to examine the effect of food on the bioavailability of the drug. The concentrations of JTP-4819 in plasma and urine were determined by electrospray ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) method. Results In the multiple-dose study, the cholinesterase activity was gradually increased and reached above the normal range on days 4 to 8 in all five subjects given JTP-4819 and gradually returned to normal range after completion of dosing. The elevation of plasma cholinesterase activity was considered to be an action of JTP-4819, but this remains to be verified. There were no other abnormal findings in objective symptoms and laboratory findings including blood pressure, heart rate, electrocardiogram, body temperature, haematology, blood chemistry and urinalysis. The C max of JTP-4819 at 30, 60 and 120 mg in fasting state were 474, 887 and 1,649 ng ml −1 , respectively, at 1 h after administration, and the t 1/2 was about 2 h.
Introduction Methods

JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glyco-
Subjects loylpyrrolidinyl]-2-pyrrolidinecarboxamide, is a recently developed orally active specific prolyl endopeptidase (PEP)
The study protocol was approved by the local Committee on Ethics of human experimentation. Thirty-four healthy inhibitor ( Figure 1 ). It has been reported that JTP-4819 increased the levels of neuropeptides in the brains of old rats male Japanese volunteers gave written informed consent to participate in the study after being fully informed of the [1, 2] , resulting in improvement of learning acquisition and memory retention in behavioural pharmacological studies using experimental amnesic rats [3] . Thus, JTP-4819 may be effective in the prevention of memory loss, disorientation in Alzheimer's disease, senile dementia of Alzheimer-type or vascular dementia. Toxicology studies in laboratory animals have shown that JTP-4819 has no clinically significant toxicity. In this study, the pharmacokinetics and safety of JTP-4819 in healthy Japanese male volunteers after single and multiple oral doses have been investigated. purpose and risks involved. The subjects were aged 22 to administration on days 1 and 4; just before dosing and then at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24 and 48 h after the final 43 years and weighed between 48.1 and 80.6 kg. They were judged to be fit for the study based on physical examination administration on day 7. On days 2, 3, 5, and 6, blood samples were also collected just before the first adminisand standard biochemical, haematological, and urinalysis screening tests. All subjects were free of other medications tration. Urine samples were collected before the first dosing and at 0-3, 3-6, 6-12 and 12-24 h after the first for at least 1 week prior and during the study. Alcohol and caffeine-containing beverages were allowed during the study. administration on days 1 and 4, at 0-3, 3-6, 6-12, 12-24 and 24-48 h after the final administration on the day 7, and at 0-24 h after the first administration on the day 2, 3, 5 Study design and 6. Plasma and urine samples were stored at −20°C until assay. Concentrations of JTP-4819 were determined Based on the principles of 'less than 1/5 of the minimal effective dosage, 0.3 mg kg −1 , obtained from pharmacology by electrospray ionization-liquid chromatography/mass spectrometry (ESI-LC/MS) in both plasma and urine. The studies' and 'less than 1/20 of the predicted clinical dosing, 1 mg kg −1 ', the initial dose of JTP-4819 was set at 3 mg. analytical methods for plasma and urine were validated, and were reproducible over the range 5 to 100 ng ml −1 in In 3 month repeated-dose toxicity studies in dogs, at doses up to 100 mg kg −1 of JTP-4819, given orally no toxic signs plasma, and 50 to 1000 ng ml −1 in urine. Intra-day and inter-day assay variability was less than 3.2% for plasma, and except for vomiting were observed.
The drug was taken in the early morning after an less than 5.5% for urine. Plasma concentrations of substance P, arginine, vasopressin, thyrotropin releasing hormone and overnight fast. Initially, as a pilot study, three groups of two subjects were given oral doses of 3, 10 and 30 mg of somatostatin were measured by radioimmunoassay and intraday and inter-day assay variability were less than 9.3, 14.4, JTP-4819, respectively. After safety assessment, 21 subjects were divided into three groups of six, eight (including two 5.6 and 9.4%, respectively [4, 5] .
In the single-dose study, subjective and objective sympgiven placebo) and seven (including one given placebo). Subjects were given 30, 60 and 120 mg of JTP-4819, toms, and vital signs including blood pressure, heart rate and body temperature were examined before and periodically respectively. In group 5 except for the two placebo subjects, the effect of food-intake on the pharmacokinetics of up to 24 h after drug administration. Routine laboratory tests including haematology, blood biochemistry and urinal-JTP-4819 was examined in a cross-over design. In the multiple-dose study, seven subjects were blindly divided ysis were performed before and 24 h after administration and a 12-lead electrocardiogram was recorded immediately into two groups of 5 (A) and two (B). Group A was given 60 mg of JTP-4819 three times daily at 08.00, 14.00 and before, and at 2, 24 h and 7 days after drug administration.
In the multiple dose study, the same measurements were 20.00 h for 6 days and 60 mg once at 08.00 h on day 7. Group B was given placebo in the same manner (Table 1) .
performed before, on days 4, 7 and then 7 days after administration. An ECG was recorded and retinal examinIn the single-dose study, plasma was obtained from each subject using a heparinized syringe before dosing and at ation was performed before and 5 to 8 h after dosing in a single-dose study at 120 mg. In a multiple dose study, an 0.25, 0.5, 1, 1.5, 2, 4, 8, 12 and 24 h after administration. Urine was collected before dosing and at 0-2, 2-4, 4-8,
EEG was recorded and a retinal examination was performed before administration and on day 6. If any abnormality was 8-12 and 12-24 h after administration. In the multiple-dose study, blood samples were collected at the following times: observed in these examinations, the subject was followed up until resolution. before dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 7, 8, 12 ( just before the second administration) 13 and 14 h after the first Preliminary animal studies demonstrated a rise in plasma Safety and tolerance additional measurements were taken on days 64 and 93 in one subject. Plasma cholinesterase activity is expressed as
In the multiple-dose study, the plasma cholinesterase activity gradually increased and reached above normal range without metabolic rate to thiocholine from butylthiocholine and the value in terms of coefficients of variation was 0.82%.
any symptoms on day 8 in all five subjects given JTP-4819 and gradually returned to normal range after completion of dosing ( Table 2 ). The elevation of plasma cholinesterase Pharmacokinetic analysis activity was considered to be a typical action of JTP-4819. There were no other abnormal findings in objective Plasma concentration-time profiles of JTP-4819 were symptoms and laboratory tests including blood pressure, analyzed using a one-compartment open model and modelheart rate, electrocardiogram, body temperature, haemaindependent methods. C max and t max were observed at peak tology, blood chemistry, urinalysis and plasma neuropeptides. concentration and time, respectively. The linear least square regression analysis was used to ascertain the elimination rate constant from the visually identified terminal linear portion
Single-dose pharmacokinetics of the concentration versus time curve. The area under the The changes in plasma concentrations of JTP-4819 after plasma concentration time curve (AUC) was calculated by oral doses of 30, 60 or 120 mg in fasting condition are log trapezoidal rule plus the quotient of the plasma shown in Figure 2 . t max values were not significantly different concentration at the last assayed point divided by the among the three doses and C max and AUC increased in elimination rate constant. The amount of JTP-4819 excreted into the urine in the collection period was calculated from the urinary concentration and volume. The urinary recovery (UR) was expressed as the percentage of the dose of JTP-4819.
For the analysis of the pharmacokinetics after repeated dosing, the values of t max , C max , t 1/2 , AUC(0,6h) (AUCt) and UR (0-6h) (URt) were obtained from plasma concentrations and urinary excretions on days 1, 4 and 7 after the first administration.
Statistical analysis
Data are presented as the mean±s.d. values. Analysis of variance (ANOVA) was used for the comparison of pharmacokinetic parameters between different doses. Student's paired t-test was used for the analysis of the effect on food intake, the changes in neuropeptides and the Table 3 Pharmacokinetic parameters of JTP-4819 in six healthy male volunteers in the single-dose study.
healthy male volunteers in the multiple-dose study (60 mg three times daily). 
Determination of neuropeptides
The concentration of plasma neuropeptides including subproportion to the given doses ( Table 3) . The values of t 1/2 stance P, arginine vasopressin, thyrotropin releasing hormone seemed to be independent of the dose and were approxiand somatostatin were determined in single-dose studies mately 2.0 h. The cumulative urinary excretion of JTP-4819 (Table 6 ). Although plasma substance P levels in the 30 mg was between 63.0 and 68.3% of the single dosage.
and 120 mg significantly increased, the increases were small The pharmacokinetic parameters in the non fasting state and were not dose related. The concentrations of plasma were compared with those whilst fasting. The plasma neuropeptides, substance P and somatostatin were examined concentration-time profiles are shown in Figure 3 . Food in the multiple-dose study. However, no drug related intake did not significantly affect the values of C max , AUC changes in the level of the two neuropeptides were observed or t max (Table 4) .
when compared with those obtained from subjects given placebo.
Multiple-dose pharmacokinetics
Discussion
The plasma concentration vs time profiles and pharmacokinetic parameters of the multiple-dose study are shown in
In the multiple-dose study, the plasma cholinesterase activity Figure 4 and Table 5 . The pharmacokinetic parameters was gradually increased and reached above the normal range obtained from the first, 10th and 19th doses were almost on day 8 in all five subjects given JTP-4819 and then, the same among doses. The values of C max after the first, gradually returned to normal range. The elevation of plasma cholinesterase activity was considered to be attributable to JTP-4819. In the course of this study, no other abnormality attributable to the test drug was observed in objective symptoms, vital signs, and routine laboratory tests, suggesting that JTP-4819 was well tolerated in healthy subjects. However, the mechanism of elevation of plasma cholinesterase activity induced by JTP-4819 is unclear to us. In a single-dose study, the values of AUC and C max appeared to be proportional to the dose, showing linear pharmacokinetics for JTP-4819. The mean values of t 1/2 , between 1.9 and 2.2 were constant regardless of the dosage. The mean cumulative excretion of JTP-4819 of urine within 24 h were between 63.0 and 68.3% of the dose. In the multiple-dose study, the pharmacokinetics data were virtually identical to those expected from the single-dose study. No significant differences in the values of C max , AUC and t 1/2 were found among the first, 10th and 19th doses. The mean urinary excretion of JTP-4819 during accumulation in plasma or urine was observed. In this study, although the increases of substance P in as obtained in this study, penetrated the blood brain barrier and inhibited PEP activity in the brain, resulting in increases doses of 30 and 120 mg were significant, the changes were small and were not dose related, and the plasma concentration in the aforementioned neuropeptides [11] . The findings suggest that the concentrations of these neuropeptides in of arginine vasopressin, thyrotropin releasing hormone and somatostatin at these dose levels were not affected by the central nervous system are increased by JTP-4819 via inhibition of PEP activity. JTP-4819, suggesting that these neuropeptides in the peripheral system may be metabolized by the isozyme of In this study, plasma cholinesterase activity was increased by JTP-4819 administration. It is known that the plasma PEP which is present at sites, other than the central nervous system [6] [7] [8] [9] [10] , and is not inhibited by JTP-4819. In animal cholinesterase activity increases in nephrosis, diabetes, fatty liver and hyperthyroidism [12] [13] [14] [15] . Further, in some families, experiments, JTP-4819, at the same plasma concentrations
